1A. What data are needed to rule out the relevance of any specific exposure measure to efficacy?
1B. What is the role of intracellular concentrations in the evaluation of new formulations and alternative dosing regimens for approved NRTIs?
1C. In what circumstances would clinical efficacy data be necessary?